Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 127.59% | 94.90% | 119.98% | 87.95% | 80.93% |
| Total Depreciation and Amortization | 11.69% | 13.03% | 13.61% | 17.34% | 16.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -113.22% | 23.00% | 3.08% | 186.79% | 258.81% |
| Change in Net Operating Assets | 8.63% | -50.31% | -4.90% | -42.17% | -40.77% |
| Cash from Operations | 119.79% | 90.67% | 166.28% | 142.55% | 153.52% |
| Capital Expenditure | -55.11% | -55.03% | -46.60% | -42.38% | -48.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -81.33% | 30.27% | 72.40% | 99.98% | 9.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.57% | 25.05% | 25.27% | -61.27% | -74.72% |
| Cash from Investing | -0.51% | -17.96% | 2.07% | -18.47% | -50.20% |
| Total Debt Issued | -25.77% | 15.33% | -17.76% | 2.53% | 2.53% |
| Total Debt Repaid | -578.36% | -103.35% | 62.69% | -10.35% | 122.66% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -42.27% | -64.32% | -943.31% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.01% | -15.04% | -14.92% | -14.98% | -15.05% |
| Other Financing Activities | 14.04% | -57.17% | -66.25% | -85.60% | -77.38% |
| Cash from Financing | -341.77% | -279.89% | -91.19% | -97.74% | 5.39% |
| Foreign Exchange rate Adjustments | 337.14% | 225.29% | -96.02% | 420.51% | -219.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 246.16% | 790.89% | 549.89% | -71.35% | 158.25% |